[用于治疗高胆固醇血症的组合疗法:初级和二级预防]
Stefania Angela Di Fusco1, Furio Colivicchi1
1U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.
概括
结合降脂剂,如他类药物和ezetimibe是有效的管理动脉样硬化心血管疾病. 这种方法改善了低密度脂蛋白胆固醇 (LDL-C) 的降低和患者的坚持与高剂量他单一治疗相比.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 预防医学 预防医学
背景情况:
- 降低低密度脂蛋白胆固醇 (LDL-C) 降低对于治疗动脉样硬化心血管疾病 (ASCVD) 至关重要.
- 与高剂量他单一治疗相比,组合疗法提供了更好的LDL-C降低和坚持.
研究的目的:
- 审查ASCVD预防的治疗目标.
- 在初级和二级预防中分析他/ezetimibe组合的证据.
- 讨论罗斯瓦斯塔丁/埃泽蒂米布对LDL-C,斑块和临床事件的影响.
主要方法:
- 临床指南和研究的文献综述.
- 对降脂剂的有效性和安全性的证据分析.
- 专注于他类药物/ezetimibe联合治疗.
主要成果:
- 组合疗法是降低LDL-C的有效和安全策略.
- 与高剂量他类药物相比,在组合治疗中观察到患者坚持治疗的改善.
- 关于二次预防中罗苏瓦斯塔丁/埃泽蒂米布的数据,涉及斑块稳定和临床结果.
结论:
- 静止素/ezetimibe联合治疗是ASCVD管理中的一个有价值的策略.
- 这种组合增强了LDL-C的降低和患者的坚持.
- 进一步的数据支持其在二次预防中的作用,影响动脉样硬化斑块和临床事件.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
522
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
522
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
146
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
146
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
127
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
127


